Vertex Pharmaceuticals Incorpor Price Today
Vertex Pharmaceuticals Incorpor
VRTX
Healthcare
$91.70B
💰
Market Cap
27.5
💸
Price to Earnings
$12.9
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
16 |
Strong Buy |
10 |
Hold |
10 |
Sell |
0 |
Strong Sell |
0 |
VRTX Price Forecast Target
355.3 👉 456.0 +28%
VRTX EPS Forecast
12.9 👉 16.2 +25%
Financials
Profit Margin
35 %
Revenue Growth
13.5 %
Dividend
$ 0
Held Percent
0.2% - Insiders
96.5% - Institutions
3.3% - Public
Major Fund Holders
-
💰 Blackrock Inc. $8.0B
-
💰 Vanguard Group Inc $7.7B
-
💰 Capital World Investors $6.1B
-
💰 FMR, LLC $5.1B
-
💰 State Street Corporation $4.3B
Stock Ideas
Howard Marks Portfolio
Meet Howard Marks, the co-founder and lead of Oaktree Capital Management, a Los Angeles-based investment firm that manages roughly $78 billion in investment capital. Marks has an impressive background in distressed debt, high yield bonds, and conver…
Louis Bacon Portfolio
Louis Bacon is the founder of Moore Capital Management and is one of the famous traders of the past two decades. His personal wealth is more than $1.5 Billion and had more than $15 Billion in AUM. He has an MBA degree from Columbia Business School.
Charlie Munger Portfolio
Charlie Munger, the renowned investor and Vice Chairman of Berkshire Hathaway, is a true titan in the world of finance. Often referred to as Warren Buffett's right-hand man, Munger's portfolio investment approach is a masterclass in disciplined and …
Ray Dalio Portfolio
Ray Dalio, a visionary entrepreneur and investment strategist, laid the foundation of Bridgewater with a clear vision in mind. His relentless pursuit of excellence, coupled with an unwavering commitment to innovation, has propelled Bridgewater to be…📮FAQ
Some Frequently Asked Questions.
The Vertex Pharmaceuticals Incorpor industry is Biotechnology
The Vertex Pharmaceuticals Incorpor sector is Healthcare
The Vertex Pharmaceuticals Incorpor forecasted predicted Price to Earnings PE ratio is 21.9
The Vertex Pharmaceuticals Incorpor Price to Earnings PE ratio is 27.5
The Market Capitalization of Vertex Pharmaceuticals Incorpor is $91.70B
There are total of 257377311 float shares with 96.5% held by Institutions and 0.2% held by insiders
The MVertex Pharmaceuticals Incorpor forecasted Earnings per Share EPS is $16.2
The Vertex Pharmaceuticals Incorpor Earnings per Share EPS is 12.9
The Vertex Pharmaceuticals Incorpor company has $5323100000 gross profits with 35 profit margins
The Vertex Pharmaceuticals Incorpor Earnings Growth is 0.125% with 0.13% quarterly earnings growth
The Vertex Pharmaceuticals Incorpor Revenue is $9505000448 with 0.135 revenue growth
The price target for Vertex Pharmaceuticals Incorpor stock is $456.0 for the high target and $315.0 for the low target
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Vertex Pharmaceuticals Incorpor is Buy, with the following breakdown:
- Buy: 16
- Strong Buy: 10
- Hold: 10
- Sell: 0
- Strong Sell: 0
The Beta of Vertex Pharmaceuticals Incorpor is 0.5
The dividend of Vertex Pharmaceuticals Incorpor is $0
The dividend yield of Vertex Pharmaceuticals Incorpor is 0.0155%
The biggest institutional and mutual fund holders of Vertex Pharmaceuticals Incorpor stock are
- Blackrock Inc.
- Vanguard Group Inc
- Capital World Investors
- FMR, LLC
The Vertex Pharmaceuticals Incorpor ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0